AAO-HNS Thyroid Cancer Tumor Board

Saturday, October 17, 2026

9:30 AM - 10:30 AM PT

Location: 515A

Moderator(s)

MR

Marika D. Russell, MD

Assistant Professor
Massachusetts Eye and Ear Infirmary/Harvard Medical School
Boston, Massachusetts, United States
Gregory W. Randolph, MD

Claire and John Bertucci Endowed Chair in Thyroid Surgical Oncology
Harvard Medical School
Westwood, Massachusetts, United States

Panelist(s)

Erin J. Buczek, MD

Associate Professor, Residency Program Director
University of Kansas
Kansas City, KS, United States
Elizabeth E. Cottrill, MD, FACS,

Professor, Residency Program Director, Co-Director Thyroid & Parathyroid Center
Thomas Jefferson University Hospital
Philadelphia, PA, United States
CN

Cherie-Ann O. O. Nathan, MD

Professor and Chair of Otolaryngology - Head & Neck Surgery
LSU-Health Shreveport
Shreveport, Louisiana, United States
AS

Ashok R. Shaha, MD

Allan H. Selig Chair in Head and Neck Surgery
Memorial Sloan-Kettering Cancer Ctr (MSK)
New York, NY, United States
JS

Joseph Scharpf, MD

Professor of Otolaryngology-Head and Neck Surgery
Cleveland Clinic
Chagrin Falls, Ohio, United States
David C. Shonka, Jr., MD

Professor
University of Virginia Medical Center
Charlottesville, Virginia, United States
Mahdi A. Shkoukani, MD

Professor & Chair
CLEVELAND CLINIC ABU DHABI
Troy, MI, United States

Disclosure(s):

Erin J. Buczek, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Moderators: Marika Russell, Greg Randolph
Panelists: Erin Buczek, Beth Cottrill, Cherie-Ann Nathan, Joe Scharpf, Ashok Shaha, Dave Shonka, Madhi Shkoukani

Program Description
This expert panel will be asked to share their experience and strategies for the work-up and management of varied clinical entities, including low-risk differentiated thyroid cancer, advanced thyroid cancer, medullary thyroid carcinoma, and anaplastic thyroid cancer. Topics to be addressed include molecular analysis, active surveillance and ablation of low-risk lesions, surgical management of the invaded recurrent laryngeal nerve, and use neoadjuvant targeted therapy for the treatment of advanced thyroid cancer. Cases will incorporate discussion of the new 2025 ATA guidelines for management of differentiated thyroid cancer.

Learning Objectives:

Appreciate the diagnostic utility and prognostic significance of mutational analysis in the diagnosis and management of thyroid cancer, including its application to initiation of neoadjuvant targeted therapy
Discuss the role of active surveillance and thermal ablation for low-risk lesions
Develop an appreciation for thoughtful and strategic management of the invaded recurrent laryngeal nerve using state-of-the-art nerve monitoring techniques